Table 3 Actual prescribing in relation to recommendations
From: Heart failure guidelines and prescribing in primary care across Europe
| Spironolactone in general not to be given in combination with ACE | ACE + spironolactone | ||||
|---|---|---|---|---|---|
| Recommendation |
Countries
(% of total) |
Year of publication
Range (mean) | (%) |
Drug use
% patients with OR (95%CI) | |
| univariate | multivariate | ||||
| All countries* |
10381 (100%) | 6.6 | |||
| Warning (Identical) |
NL, Cz, F, D, Swe (36,5%) |
1995–1998 (1997) | 5,7 |
0.78 (0.66–0.91) |
0.74 (0.63–.87) |
| no warning/no recommendation† |
Remaining (63,5%) |
1998 (1998) | 7,2 | 1 | 1 |
| β-blockers are indicated only for patients with IDCM (idiopathic dilated cardiomyopathy) | β-blocker | ||||
| All countries* |
10381 (100%) | 33.8 | |||
| Restricted indication (identical) |
Cz, H, CH, UK (28.6%) |
1998 (1998) | 40.4 | 1 | 1 |
| No restriction |
Remaining†
(71.4%) |
1995–1998 (1997) | 31.1 |
0.67 (0.61–0.73) |
0.69 (0.63–0.76) |